sglt2 glp-1 news vs GLP-1: Individualizing Diabetes, Cardiovascular, and Renal Outcomes Efficacy and safety of SGLT2

A new briefing from the Californian-based think tank Pacific Research Institute (PRI) warns that continued large-scale sales are not only putting patients at risk but could wipe out between $9.3bn and $11.8bn in future R&D investment enough to cost the world four to five new medicines

[DOI] [PMC free article] [PubMed] [Google Scholar] Zimmermann K

loading...Please select quantityGet Quote August 31 Please select quantity August 31 Get Quote loading

Rationale for nicotinamide adenine dinucleotide (NAD+) metabolome disruption as a pathogenic mechanism of post-acute COVID-19 syndrome

PharmCon freeCE provides flexible, accredited continuing education for pharmacy teams, helping them stay compliant, build clinical skills, and improve patient care